The shadow of generic challenges has consistently loomed around copyright’s famous drug, Viagra, triggering questions about the outlook of similar pharmaceutical stakes. While initial years saw substantial returns, the patent lapse has created the door for discounted copies, potentially reducing profitability and posing a real hazard for sharehol